Celcuity, a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, entered into an amendment to its existing senior secured credit facility with an affiliate of Innovatus Capital Partners and Oxford Finance and its affiliates. The amendment increases the total term loan facility size to $500 million, including $350 million in committed capital and up to $150 million at the mutual discretion of Celcuity and its lenders. At the closing of the amendment, the initial funding under the amended credit facility was in a principal amount of $30 million, bringing the total term loan outstanding to $130 million.
Highlights of the amended credit facility include:
- Increased Capital Availability: Adds $170 million in new committed capital, including an additional $50 million for a total of $100 million available upon U.S. Food and Drug Administration (FDA) approval of gedatolisib in second-line wild-type advanced breast cancer (ABC) patients post-CDK4/6 inhibitor therapy, and $120 million upon achievement of certain commercial revenue milestones. An additional up to $150 million is also available at the mutual discretion of Celcuity and its lenders.
- Improved Structure and Financial Flexibility: Extends the interest-only period by 14 months, with an additional seven-month extension available upon FDA approval. The maturity date of the facility was also extended by six months.
The upsized facility strengthens Celcuity’s ability to manage its capital structure efficiently while providing additional funding to support the rolling submission to FDA of its New Drug Application via FDA’s RTOR program, commercial launch preparations for gedatolisib and other strategic initiatives.
